Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299269 | 0.91 | MEN1 (0.45) | L3MBTL3L3MBTL1ALDH1A1TSHRHRH3 | |
| SCHEMBL30299348 | 0.84 | GPR4 (0.42) | ALDH1A1TSHRHRH3KDM4EKMT2A | |
| SCHEMBL30299358 | 0.83 | GPR4 (0.43) | L3MBTL1ALDH1A1RECQLTSHRHRH3 | |
| SCHEMBL30299283 | 0.82 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL30299315 | 0.80 | LMNA (0.52) | ALDH1A1HRH3KDM4E | |
| SCHEMBL30299344 | 0.78 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1ALDH1A1 | |
| SCHEMBL30299323 | 0.78 | NPY2R (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1ALDH1A1 | |
| SCHEMBL30299376 | 0.77 | GPR4 (0.38) | — | |
| SCHEMBL30299339 | 0.77 | HRH3 (0.39) | ALDH1A1HRH3KDM4E | |
| SCHEMBL30276325 | 0.76 | AXL (0.36) | L3MBTL3L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |